Characteristics of 5 patients with refractory T-cell malignancies treated with forodesine
Patient no. . | Age, y/sex . | Diagnosis . | Prior therapy (response) . | Salvage no. . | Sites of disease . | WBC count/ANC, × 109/L . | Hgb,*g/dL . | Platelet count,*× 109/L . |
|---|---|---|---|---|---|---|---|---|
| 1 | 35/M | T-ALL† | CALGB regimen with XRT Med (CR, 24 mos); mitoxantone and cytarabine (NR); hyper-CVAD (PR, 2 months); methotrexate and L-asparaginase (NR) | 4 | BM, PB, LN, pleural effusion | 4.4/3.5 | 9.3 | 11 |
| 2 | 73/F | T-PLL | FCR × 2 (NR); CHOP (NR) | 2 | BM, PB | 121.3/3.8 | 10.4 | 40 |
| 3 | 52/F | T-PLL | FCR × 6 (PR, 6 mo) | 1 | BM, PB, LN, spleen | 87.1/2.6 | 8.6 | 50 |
| 4 | 35/M | T-ALL† | Hyper-CVAD with XRT Med (CR, 32 mo); methotrexate and cytarabine (PR) | 2 | BM, PB, Med | 14.8/2.4 | 9.1 | 36 |
| 5 | 70/M | T-PLL | Fludarabine (NR); alemtuzumab (NR); denileukin diftitox (NR); CVP (NR) | 5 | BM, PB, LN, spleen | 150.6/12.1 | 8.7 | 24 |
Patient no. . | Age, y/sex . | Diagnosis . | Prior therapy (response) . | Salvage no. . | Sites of disease . | WBC count/ANC, × 109/L . | Hgb,*g/dL . | Platelet count,*× 109/L . |
|---|---|---|---|---|---|---|---|---|
| 1 | 35/M | T-ALL† | CALGB regimen with XRT Med (CR, 24 mos); mitoxantone and cytarabine (NR); hyper-CVAD (PR, 2 months); methotrexate and L-asparaginase (NR) | 4 | BM, PB, LN, pleural effusion | 4.4/3.5 | 9.3 | 11 |
| 2 | 73/F | T-PLL | FCR × 2 (NR); CHOP (NR) | 2 | BM, PB | 121.3/3.8 | 10.4 | 40 |
| 3 | 52/F | T-PLL | FCR × 6 (PR, 6 mo) | 1 | BM, PB, LN, spleen | 87.1/2.6 | 8.6 | 50 |
| 4 | 35/M | T-ALL† | Hyper-CVAD with XRT Med (CR, 32 mo); methotrexate and cytarabine (PR) | 2 | BM, PB, Med | 14.8/2.4 | 9.1 | 36 |
| 5 | 70/M | T-PLL | Fludarabine (NR); alemtuzumab (NR); denileukin diftitox (NR); CVP (NR) | 5 | BM, PB, LN, spleen | 150.6/12.1 | 8.7 | 24 |
Hgb indicates hemoglobin; CALGB, Cancer and Leukemia Group B; XRT, irradiation; CR, complete response; NR, no response; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; PR, partial response; BM, bone marrow; PB, peripheral blood; LN, lymphadenopathy; FCR, fludarabine, cyclophosphamide, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; Med, mediastinum; CVP, cyclophosphamide, vincristine, prednisone.
All patients were transfusion-dependent for packed red blood cells and platelets prior to study entry
Original diagnosis T-LL, relapsed as T-ALL owing to bone marrow disease (Table 2)